General Information of Drug (ID: DM0LXBW)

Drug Name
RG-7256 Drug Info
Synonyms B-raf inhibitor (melanoma), Roche/Plexxikon
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Discontinued in Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM0LXBW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dabrafenib DMX6OE3 Melanoma 2C30 Approved [3]
Vemurafenib DM62UG5 Melanoma 2C30 Approved [4]
LGX818 DMNQXV8 Melanoma 2C30 Approved [5]
PLX8394 DMRTD7I Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
CEP-32496 DMAO04B Solid tumour/cancer 2A00-2F9Z Phase 1/2 [7]
BGB-283 DMVYTG7 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [8]
ARQ 736 DMP9ZT1 Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
RO-5212054 DML4C3Q Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
ASN003 DMJCX6D Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
BMS-908662 DM3K8VM Solid tumour/cancer 2A00-2F9Z Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serine/threonine-protein kinase B-raf (BRAF) TTWCGQT BRAF_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022593)
2 First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors. Target Oncol. 2016 Apr;11(2):149-56.
3 Clinical pipeline report, company report or official report of GlaxoSmithKline (2011).
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
6 Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 2014 Mar;27(2):253-62.
7 Clinical pipeline report, company report or official report of Ambit Biosciences.
8 BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14(10):2187-97.
9 National Cancer Institute Drug Dictionary (drug id 688029).
10 National Cancer Institute Drug Dictionary (drug id 680347).
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12 Clinical pipeline report, company report or official report of Exelixis (2011).